CareDx

Timeline

1. Aug 31, 2026 Trial start —: Forecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS Patients (FORWARD) source ↗
2. 2025-12 Trial start Not phased (device or behavioral study): HeartCare Immuno-optimization in Cardiac Allografts (MOSAIC) source ↗
3. 2022-08 Trial start Not phased (device or behavioral study): KidneyCare Immuno-optimization in Renal Allografts (KIRA) source ↗
4. Oct 29, 2021 Trial start —: AlloSure Lung Assessment and Metagenomics Outcomes Study source ↗
5. Oct 26, 2021 Trial start —: Technology Enabled And Molecular Monitoring of the Allograft and Transplant rEcipient source ↗
6. Jun 30, 2021 Trial start —: Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test source ↗
7. May 26, 2021 Trial start —: Molecular Assessment and Profiling of Liver Transplant Recipients source ↗
8. Nov 19, 2020 Trial start —: Transition of Renal Patients Using AlloSure Into Community Kidney Care source ↗
9. Apr 1, 2020 Trial start —: AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience source ↗
10. Mar 1, 2019 Trial start —: Assessing AlloSure Dd-cfDNA Monitoring Insights of Renal Allografts With Longitudinal Surveillance source ↗
11. Dec 28, 2018 Trial start —: Surveillance HeartCare® Outcomes Registry source ↗
12. Jan 23, 2018 Trial start —: Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry source ↗
13. 2015-04 Trial start —: Non Invasive Blood Test To Diagnose Acute Rejection After Kidney Transplantation source ↗
14. 2014-06 Trial start —: Utility of Donor-Derived Cell Free DNA in Association With Gene Expression Profiling source ↗
15. 2013-03 Trial start —: Outcomes AlloMap Registry: the Long-term Management and Outcomes of Heart Transplant Recipients With AlloMap Testing source ↗

Upcoming milestones

• Oct 15, 2026 (ESTIMATED) · · Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test · NCT04635384
• 2026-11 (ESTIMATED) · · Surveillance HeartCare® Outcomes Registry · NCT03695601
• Dec 31, 2027 (ESTIMATED) · · Molecular Assessment and Profiling of Liver Transplant Recipients · NCT04793360
• Dec 31, 2028 (ESTIMATED) · · AlloSure Lung Assessment and Metagenomics Outcomes Study · NCT05050955
• Dec 31, 2029 (ESTIMATED) · · Forecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS Patients (FORWARD) · NCT07607327

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 15

NIH awards 1

Annual award amounts. Total $268K.

• Mar 27, 2015 NIH award 6R43HL117394-02 FY2013: $267,693 awarded for that fiscal year; activity R43 (SBIR); PI WOODWARD, ROBERT; recipient as written: CAREDX, INC., BRISBANE, CA. High-specificity, non-invasive methods for monitori source ↗

Open jobs 36

2 patient-care jobs hidden (phlebotomy, plasma-center, nursing and similar care roles; 38 open jobs in total). Show patient-care jobs (2)

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.